What are the Challenges with Dengue Vaccines and How is Takeda Addressing Them?

What are the Challenges with Dengue Vaccines and How is Takeda Addressing Them?FILE - In this Tuesday, Dec. 5, 2017 file photo, a Manila Health officer shows off a pair of vials of the anti-dengue vaccine Dengvaxia in Manila, Philippines. The World Health Organization says that the first-ever vaccine for dengue needs to be dealt with in “a much safer way.” It said the shot should mostly be given to people who have previously been infected with the disease. In November, the vaccine’s manufacturer, Sanofi Pasteur, said that people who had never been sickened by dengue before were at risk of developing more serious disease after getting the shot. (AP Photo/Bullit Marquez, file)

WHO Prequalifies Second Dengue Vaccine: TAK-003

Challenges in Dengue Vaccine Development

Dengue vaccines have faced challenges in development, primarily due to the virus’s unique characteristics and the need for a safe and effective vaccine that protects against all four serotypes.

Takeda’s Approach to Addressing Challenges

Takeda’s TAK-003 vaccine addresses these challenges with its innovative design and clinical data.

Broad Protection Against All Dengue Serotypes

TAK-003 is a live-attenuated vaccine containing weakened forms of all four dengue virus serotypes. This approach aims to provide broad protection against the different strains of the virus, which can vary geographically.

Phase 3 Clinical Trial Results

Phase 3 clinical trials involving over 20,000 participants showed promising results. TAK-003 demonstrated:

* 80.2% protection against symptomatic dengue cases at the end of one year
* 90.4% prevention of hospitalization at 18 months

Safety and Efficacy Profile

TAK-003 has been evaluated in extensive clinical trials and has shown a favorable safety and efficacy profile. It has been generally well-tolerated, with mild and transient side effects similar to other vaccines.

Potential for Future Impact

The WHO’s prequalification of TAK-003 is a significant step towards expanding access to dengue vaccination globally. The vaccine has the potential to protect millions of people, particularly in regions where dengue is a major public health concern.


Takeda’s TAK-003 vaccine represents a significant advancement in dengue vaccine development, addressing the challenges associated with broad protection and safety. With the WHO’s prequalification, this vaccine is poised to play a crucial role in combating dengue and reducing its impact on global health.

By Deepika

Related Post

Leave a Reply

Your email address will not be published. Required fields are marked *